Photo from hmpgloballearningnetwork.com
Jun 17, 2023, 15:37
Super results in transfusion-dependent patients on ruxolitinib – Francesco Passamonti
It was a great honor to present at EHA 2023 on behalf of all investigators results of the ACE-536-MF-001 trial on luspatercept in patients with myelofibrosis and anemia. Super results in transfusion-dependent patients on ruxolitinib: a 32% rate of transfusion-independency over time with 53% of the patients with >50% reduction of transfusion burden. This allowed to keep stable the dose of ruxolitinib and the spleen size. All with a safe profile!
Source: Francesco Passamonti/Linkedin